COVID-19
Showing NaN - NaN of 31
SARS-CoV-2 Infection, COVID-19 Trial in United States (BNT162b2 (Omi XBB.1.5))
Not yet recruiting
- SARS-CoV-2 Infection
- COVID-19
- BNT162b2 (Omi XBB.1.5)
-
Dublin, California
- +14 more
Aug 10, 2023
COVID-19 Trial in United States (XBB.1.5 Vaccine (Booster), XBB.1.5 Vaccine (single dose))
Not yet recruiting
- COVID-19
- XBB.1.5 Vaccine (Booster)
- XBB.1.5 Vaccine (single dose)
-
Mobile, Alabama
- +29 more
Aug 4, 2023
COVID-19 Trial in United States (NVX-CoV2373, SARS-CoV-2 rS antigen/Matrix-M Adjuvant)
Active, not recruiting
- COVID-19
- NVX-CoV2373
- SARS-CoV-2 rS antigen/Matrix-M Adjuvant
-
Austin, Texas
- +4 more
May 16, 2023
Long-Term Sequelae of SARS-COV-2 Infection: Diabetes Mellitus
Not yet recruiting
- COVID-19
- Diabete Mellitus
- Measure of physiologic parameters
-
San Antonio, TexasTexas Diabetes Institute - University Health System
May 17, 2023
COVID-19 Trial in Canada, United Kingdom, United States (mRNA-1283.222, mRNA-1273.222)
Recruiting
- COVID-19
- mRNA-1283.222
- mRNA-1273.222
-
Birmingham, Alabama
- +209 more
Apr 13, 2023
SARS-CoV2 Infection, Covid19, SARS-CoV-2 Acute Respiratory Disease Trial in Worldwide (BNT162b2, BNT162b2 (B.1.1.7 + B.1.617.2),
Active, not recruiting
- SARS-CoV2 Infection
- +3 more
- BNT162b2
- +5 more
-
Long Beach, California
- +34 more
Jan 10, 2023
COVID-19 Trial in Worldwide (AZD7442, Placebo)
COVID-19, Cardiovascular Diseases, Cardiovascular Risk Factor Trial in Brazil, Mexico, United States (Cannabidiol,
Terminated
- COVID-19
- +2 more
- Cannabidiol, pharmaceutically produced with < 5 ppm THC
- Placebo
-
Phoenix, Arizona
- +19 more
Dec 12, 2022
COVID-19 Trial in Puerto Rico, United States (Convalescent Plasma, Masked Saline Placebo)
Terminated
- COVID-19
- Convalescent Plasma
- Masked Saline Placebo
-
Birmingham, Alabama
- +23 more
Sep 9, 2022
COVID-19 Trial in United States (Biological/Vaccine: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), SARS-CoV-2
Recruiting
- COVID-19
- Biological/Vaccine: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)
- +3 more
-
Little Rock, Arkansas
- +24 more
Aug 2, 2022
COVID-19 Trial in Worldwide (SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent), SARS-CoV-2 adjuvanted recombinant
Active, not recruiting
- COVID-19
- SARS-CoV-2 adjuvanted recombinant protein vaccine (monovalent)
- +2 more
-
Birmingham, Alabama
- +93 more
Jul 22, 2022
COVID-19 Trial in Korea, Republic of, United States (biological, other, drug)
Completed
- COVID-19
- Lenzilumab
- +2 more
-
Birmingham, Alabama
- +55 more
Jul 21, 2022
COVID-19, SARS-CoV-2 Trial in Chile, Peru, United States (AZD1222, Placebo)
Active, not recruiting
- COVID-19
- SARS-CoV-2
- AZD1222
- Placebo
-
Phoenix, Arizona
- +83 more
Jul 13, 2022
COVID-19, SARS-CoV-2 Infection Trial in United States (NVX-Cov2373)
Active, not recruiting
- COVID-19
- SARS-CoV-2 Infection
-
Long Beach, California
- +30 more
Jul 18, 2022
SARS-CoV-2 Infection, COVID-19 Trial in Worldwide (BNT162b2, Placebo, BNT162b2 OMI)
Recruiting
- SARS-CoV-2 Infection
- COVID-19
- BNT162b2
- +4 more
-
Athens, Alabama
- +158 more
Jul 18, 2022
From Coronavirus Disease 2019 Vaccinated Adults and Adolescents
Terminated
- COVID-19
-
Boston, Massachusetts
- +31 more
Mar 24, 2022
Pneumococcal Disease, COVID-19, SARS-CoV-2 Infection Trial in United States (20-valent pneumococcal conjugate vaccine (20vPnC),
Completed
- Pneumococcal Disease
- +2 more
- 20-valent pneumococcal conjugate vaccine (20vPnC)
- +2 more
-
Anaheim, California
- +28 more
Mar 23, 2022